Janux Therapeutics
JANX
45 hedge funds and large institutions have $571M invested in Janux Therapeutics in 2021 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 9 increasing their positions, 8 reducing their positions, and 9 closing their positions.
167% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 9
50% more funds holding
Funds holding: 30 → 45 (+15)
13% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 8
1.67% more ownership
Funds ownership: 62.01% → 63.68% (+1.7%)
7% less capital invested
Capital invested by funds: $614M → $571M (-$43.3M)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$51M |
| 2 |
BlackRock
New York
|
+$19.9M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$14.4M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$5.46M |
| 5 |
State Street
Boston,
Massachusetts
|
+$5.02M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$17.5M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
-$8.63M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
-$7.24M |
| 4 |
SB
Samsara BioCapital
Palo Alto,
California
|
-$5.64M |
| 5 |
BI
BVF Inc
San Francisco,
California
|
-$4.59M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ECM
51
ExodusPoint Capital Management
New York
| – | -$613K | -24,567 | Closed |
|
52
Qube Research & Technologies (QRT)
London,
United Kingdom
| – | -$357K | -14,309 | Closed |
|
53
Wellington Management Group
Boston,
Massachusetts
| – | -$229K | -9,165 | Closed |
|
JANX Hedge Fund Activity: Q3 2021 in Review
45 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Janux Therapeutics (JANX) for Q3 2021, worth a combined $571M — down 7% from $614M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new JANX positions and 9 closed out — a net gain of 15 holders — while 9 added to existing stakes and 8 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $51M. The largest seller was Deerfield Management, exiting entirely with an estimated $17.5M sold.
- 45 institutional investors held Janux Therapeutics (JANX) as of Q3 2021, up from 30 in Q2 2021.
- Funds reported $571M of Janux Therapeutics stock for Q3 2021, down 7% quarter-over-quarter.
- 24 funds opened new Janux Therapeutics positions in Q3 2021 and 9 closed out, a net change of +15 holders.
- The largest Janux Therapeutics buyer in Q3 2021 was Fidelity Investments, an estimated $51M added.
- The largest Janux Therapeutics seller in Q3 2021 was Deerfield Management, an estimated $17.5M sold.
Based on aggregated 13F filings for Q3 2021.